Cowen analyst Phil Nadeau said that while the FDA briefing docs on Biogen's (NASDAQ: BIIB) Adu were positive, they were ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE